Skip to main content
. 2020 Oct 21;12:580564. doi: 10.3389/fnagi.2020.580564

Table 1.

Demographic and clinical characteristic of the participants.

Variables PD-FOG (n = 23) PD-nFOG (n = 33) HC (n = 24) P-values
Gender, Male/Female 11/12 18/15 12/12 0.875d
Age (years) 65.00 ± 6.59 63.79 ± 8.35 62.29 ± 6.03 0.189a
MMSE 25.63 ± 3.43 26.09 ± 4.13 27.25 ± 1.96 0.366a
Disease duration (years) 6.02 ± 5.27 3.27 ± 3.30 NA 0.007b
Hoehn & Yahr stage 2.45 ± 0.52 2.09 ± 0.46 NA 0.018b
UPDRS-I 2.08 ± 2.27 1.05 ± 1.51 NA 0.046b
UPDRS-II 10.98 ± 6.80 7.23 ± 4.12 NA 0.011c
UPDRS-III 28.78 ± 1.76 27.86 ± 1.32 NA 0.820c
UPDRS-IV 2.87 ± 2.94 0.77 ± 1.40 NA 0.001b
GFQ 16.22 ± 1.27 3.4 ± 2.79 NA 0.001b
FOGQ 9.59 ± 6.41 1.60 ± 1.64 NA 0.001b
LEDD 494.51 ± 309.35 316.63 ± 188.76 NA 0.010c

Data were presented as means ± standard deviations. Abbreviations: PD-FOG, Parkinson’s disease with freezing of gait; PD-nFOG, Parkinson’s disease without freezing of gait; MMSE, Mini-Mental State Examination; UPDRS, Unified Parkinson’s Disease Rating Scale; GFQ, Gait and Falls Questionnaire; FOGQ, Freezing of Gait Questionnaire; NA, not applicable. aP-values for comparisons between the three groups obtained using Kruskal-Wallis H test; bP-values for differences between PD-FOG and PD-nFOG participants obtained using Mann-Whitney U test; cP-values for comparisons between PD-FOG and PD-nFOG participants obtained two-sample t-test; dP-values obtained using χ2 test between the three groups.